Outlook Therapeutics(OTLK.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Outlook Therapeutics
OTLK.US
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora.
1.878 T
OTLK.USMarket value -Rank by Market Cap -/-

Financial Score

13/06/2026 Update
D
BiotechnologyIndustry
Industry Ranking269/390
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE198.37%A
    • Profit Margin-18297.50%E
    • Gross Margin-17.18%E
  • Growth ScoreD
    • Revenue YoY0.00%D
    • Net Profit YoY-388.61%E
    • Total Assets YoY14.77%B
    • Net Assets YoY10.68%B
  • Cash ScoreC
    • Cash Flow Margin77.18%C
    • OCF YoY0.00%D
  • Operating ScoreE
    • Turnover0.02E
  • Debt ScoreE
    • Gearing Ratio232.44%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Lennar Reports Mixed Q2 Results, Joins Adobe And Other Big Stocks Moving Lower In Friday's Pre-Market Session

    benzinga_article·
    US
    MBX
    -4.67%
    US
    RR
    -7.39%
    US
    ELMT
    +5.22%
    benzinga_article·
    US
    MBX
    -4.67%
    US
    RR
    -7.39%
    US
    ELMT
    +5.22%

    12 Health Care Stocks Moving In Wednesday's Intraday Session

    benzinga_article·
    US
    PMI
    -1.21%
    US
    RGNT
    -21.05%
    US
    INDP
    +0.28%
    benzinga_article·
    US
    PMI
    -1.21%
    US
    RGNT
    -21.05%
    US
    INDP
    +0.28%

    Tuesday 6/2 Insider Buying Report: HOOD, OTLK

    nasdaq·
    US
    OTLK
    +10.91%
    US
    HOOD
    +1.04%
    nasdaq·
    US
    OTLK
    +10.91%
    US
    HOOD
    +1.04%

    Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg) | OTLK Stock News

    StockTitan·
    US
    OTLK
    +10.91%
    StockTitan·
    US
    OTLK
    +10.91%

    Outlook Therapeutics sells 8.54M shares in registered direct offering to GMS Ventures

    TradingView·
    US
    OTLK
    +10.91%
    US
    IBB
    +0.10%
    US
    VHT
    -0.12%
    TradingView·
    US
    OTLK
    +10.91%
    US
    IBB
    +0.10%
    US
    VHT
    -0.12%
    © 2026 Longbridge｜Disclaimer